ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment

Stroke

Volumn 48, Issue 5, 2017, Pages 1262-1270

  Guekht, Alla ^a   Skoog, Ingmar ^b   Edmundson, Sally ^c   Zakharov, Vladimir ^a   Korczyn, Amos D ^d  

^a PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c Takeda Global Research and Development Centre Europe   (United Kingdom)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Actovegin; post stroke cognitive impairment; stroke; vascular dementia

Indexed keywords

ACTOVEGIN; AMINO ACID DERIVATIVE; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ELECTROLYTE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; ANTIOXIDANT; HEME;

ADULT; ADVERSE OUTCOME; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COGNITION ASSESSMENT; COGNITIVE DEFECT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONTREAL COGNITIVE ASSESSMENT; MULTICENTER STUDY; OUTCOME ASSESSMENT; POSTSTROKE COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; AGED; ANALOGS AND DERIVATIVES; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COGNITIVE DYSFUNCTION; COMPLICATION; FOLLOW UP; MIDDLE AGED; RECURRENT DISEASE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIOXIDANTS; BRAIN ISCHEMIA; COGNITIVE DYSFUNCTION; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEME; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RECURRENCE; STROKE;

EID: 85018836769     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.116.014321     Document Type: Article

References (41)

1. Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, et al; Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Experts Group. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014;383:245-254. doi: 10.1016/S0140-6736(13)61953-4.
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095-2128. doi: 10.1016/S0140-6736(12)61728-0.
3. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197-2223. doi: 10.1016/S0140-6736(12)61689-4.
4. Rajan KB, Aggarwal NT, Wilson RS, Everson-Rose SA, Evans DA. Association of cognitive functioning, incident stroke, and mortality in older adults. Stroke. 2014;45:2563-2567. doi: 10.1161/STROKEAHA.114.005143.
5. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 2009;8:1006-1018. doi: 10.1016/S1474-4422(09)70236-4.
6. Brainin M, Tuomilehto J, Heiss WD, Bornstein NM, Bath PM, Teuschl Y, et al; Post Stroke Cognition Study Group. Post-stroke cognitive decline: an update and perspectives for clinical research. Eur J Neurol. 2015;22:229-238, e13. doi: 10.1111/ene.12626.
7. Lakhan SE, Kirchgessner A, Hofer M. Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med. 2009;7:97. doi: 10.1186/1479-5876-7-97.
8. Ritter A, Pillai JA. Treatment of vascular cognitive impairment. Curr Treat Options Neurol. 2015;17:367. doi: 10.1007/s11940-015-0367-0.
9. Guekht AB, Moessler H, Novak PH, Gusev EI; Cerebrolysin Investigators. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. J Stroke Cerebrovasc Dis. 2011;20:310-318. doi: 10.1016/j. jstrokecerebrovasdis.2010.01.012.
10. Machicao F, Muresanu DF, Hundsberger H, Pflüger M, Guekht A. Pleiotropic neuroprotective and metabolic effects of Actovegin's mode of action. J Neurol Sci. 2012;322:222-227. doi: 10.1016/j.jns.2012.07.069.
11. Kuninaka T, Senga Y, Senga H, Weiner M. Nature of enhanced mitochondrial oxidative metabolism by a calf blood extract. J Cell Physiol. 1991;146:148-155. doi: 10.1002/jcp.1041460119.
12. Elmlinger MW, Kriebel M, Ziegler D. Neuroprotective and anti-oxidative effects of the hemodialysate Actovegin on primary rat neurons in vitro. Neuromolecular Med. 2011;13:266-274. doi: 10.1007/s12017-011-8157-7.
13. Hoyer S, Betz K. Elimination of the delayed postischemic energy deficit in cerebral cortex and hippocampus of aged rats with a dried, deproteinized blood extract (Actovegin). Arch Gerontol Geriatr. 1989;9:181-192.
14. Krüger G, Quadbeck G. [The electroencephalogram of the rat in oxygen deficiency as an indicator of drug effects on cerebral metabolism]. Arzneimittelforschung. 1972;22:451-456.
15. Lanner G, Argyropoulos. [Pharmacological effect of Solcoseryl on the metabolism of the brain. Animal experiments and clinical research]. Wien Med Wochenschr. 1975;125:681-685.
16. Meilin S, Machicao F, Elmlinger M. Treatment with Actovegin improves spatial learning and memory in rats following transient forebrain ischaemia. J Cell Mol Med. 2014;18:1623-1630. doi: 10.1111/jcmm.12297.
17. Saletu B, Küfferle B, Anderer P, Grünberger J, Steinberger K. EEGbrain mapping in schizophrenics with predominantly positive and negative symptoms. Comparative studies with remoxipride/haloperidol. Eur Neuropsychopharmacol. 1990;1:27-36.
18. Semlitsch HV, Anderer P, Saletu B, Hochmayer I. Topographic mapping of cognitive event-related potentials in a double-blind, placebocontrolled study with the hemoderivative Actovegin in age-associated memory impairment. Neuropsychobiology. 1990;24:49-56.
19. Derev'yannykh EA, Bel'skaya GN, Knoll EA, Krylova LG, Popov DV. Experience in the use of Actovegin in the treatment of patients with cognitive disorders in the acute period of stroke. Neurosci Behav Physiol. 2008;38:873-875. doi: 10.1007/s11055-008-9051-0.
20. Shamalov NA, Stakhovskaia LV, Shetova IM, Efremova NM, Anisimov KV. [Efficacy and safety of the combined therapy with citicholine and actovegin in the acute period of ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(9 pt 2):13-17.
21. Søndergård SD, Dela F, Helge JW, Larsen S. Actovegin, a non-prohibited drug increases oxidative capacity in human skeletal muscle. Eur J Sport Sci. 2016;16:801-807. doi: 10.1080/17461391.2015.1130750.
22. Actovegin 80 mg Injection Solution-Summary of Product Characteristics (SPC). Http://www.Pharmazie.Com/graphic/a/17/2-00017.Pdf. Accessed November 15, 2016.
23. Ramipril 1.25 mg Capsules-Summary of Product Characteristics (SPC). Https://www.Medicines.Org.Uk/emc/medicine/24132. Accessed November 15, 2016.
24. Memantine Accord 20 mg Film-Coated Tablets-Summary of Product Characteristics (SPC). Https://www.Medicines.Org.Uk/emc/medicine/28669. Accessed November 15, 2016.
25. Guekht A, Skoog I, Korczyn AD, Zakharov V, Eeg M, Vigonius U. A randomised, double-blind, placebo-controlled trial of Actovegin in patients with post-stroke cognitive impairment: ARTEMIDA Study Design. Dement Geriatr Cogn Dis Extra. 2013;3:459-467. doi: 10.1159/000357122.
26. European Medicines Agency. Guideline on Missing Data in Confirmatory Clinical Trials. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/09/WC500096793.pdf. Accessed April 11, 2017.
27. Ankolekar S, Geeganage C, Anderton P, Hogg C, Bath PM. Clinical trials for preventing post stroke cognitive impairment. J Neurol Sci. 2010;299:168-174. doi: 10.1016/j.jns.2010.08.052.
28. Cano SJ, Posner HB, Moline ML, Hurt SW, Swartz J, Hsu T, et al. The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts. J Neurol Neurosurg Psychiatry. 2010;81:1363-1368. doi: 10.1136/jnnp.2009.204008.
29. Skinner J, Carvalho JO, Potter GG, Thames A, Zelinski E, Crane PK, et al; Alzheimer's Disease Neuroimaging Initiative. The Alzheimer's Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI. Brain Imaging Behav. 2012;6:489-501. doi: 10.1007/s11682-012-9166-3.
30. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148:379-397.
31. Winblad B, Brodaty H, Gauthier S, Morris JC, Orgogozo JM, Rockwood K, et al. Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry. 2001;16:653-666.
32. Burton L, Tyson SF. Screening for cognitive impairment after stroke: a systematic review of psychometric properties and clinical utility. J Rehabil Med. 2015;47:193-203. doi: 10.2340/16501977-1930.
33. Pendlebury ST, Mariz J, Bull L, Mehta Z, Rothwell PM. MoCA, ACE-R, and MMSE versus the National Institute of Neurological Disorders and Stroke-Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards Neuropsychological Battery after TIA and stroke. Stroke. 2012;43:464-469. doi: 10.1161/STROKEAHA.111.633586.
34. Black SE. Vascular cognitive impairment: epidemiology, subtypes, diagnosis and management. J R Coll Physicians Edinb. 2011;41:49-56. doi: 10.4997/JRCPE.2011.121.
35. Korczyn AD. Mixed dementia - the most common cause of dementia. Ann N Y Acad Sci. 2002;977:129-134.
36. European Medicines Agency. Guideline on Medicinal Products for the Treatment of Alzheimer's Disease and Other Dementias. http://www.ema. europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003562.pdf. Accessed April 11, 2017.
37. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al; American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:2672-2713. doi: 10.1161/STR.0b013e3182299496.
38. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695-699. doi: 10.1111/j.1532-5415.2005.53221.x.
39. Koski L. Validity and applications of the Montreal cognitive assessment for the assessment of vascular cognitive impairment. Cerebrovasc Dis. 2013;36:6-18. doi: 10.1159/000352051.
40. Burn J, Dennis M, Bamford J, Sandercock P, Wade D, Warlow C. Longterm risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project. Stroke. 1994;25:333-337.
41. Buchmayer F, Pleiner J, Elmlinger MW, Lauer G, Nell G, Sitte HH. Actovegin®: a biological drug for more than 5 decades. Wien Med Wochenschr. 2011;161:80-88. doi: 10.1007/s10354-011-0865-y.